Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 19.36
BBH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 19.36 )
Ranked among companies with meaningful P/E(ttm) only.
BBH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 19.54
Current: 19.36
0
19.54
PE(NRI) 19.36
BBH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 19.36 )
Ranked among companies with meaningful PE(NRI) only.
BBH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 19.54
Current: 19.36
0
19.54
P/B 6.03
BBH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 6.03 )
Ranked among companies with meaningful P/B only.
BBH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 6.11
Current: 6.03
0
6.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.32
BBH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.32 )
Ranked among companies with meaningful Dividend Yield only.
BBH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.32
Current: 0.32
0
0.32
Yield on cost (5-Year) 0.32
BBH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.32 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BBH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.32
Current: 0.32
0
0.32

More Statistics

Short Percentage of Float0.00%
52-Week Range $95.56 - 144.66
Shares Outstanding (Mil)6,096,503.00
» More Articles for BBH

Headlines

Articles On GuruFocus.com
EBIX – A Long Term Winner May 26 2016 
Wally Weitz Sells Stake in Endo International, a Stock Down 75% May 26 2016 
Costco Wholesale: A Top Buy May 26 2016 
Indexes Lower With Housing Market Continuing to Show Improvement May 26 2016 
Is Apple’s Didi Investment More About R&D Than Tie-Ups? May 26 2016 
Emerson Electric: High-Yield, Sound Valuation and 59 Straight Years of Dividend Increases, Part 2 May 26 2016 
Should You Buy Alcoa Now or After the Split? May 26 2016 
Whitney Tilson: Buffett's IBM Investment Is Value Trap May 26 2016 
Lee Ainslie Raises Priceline Group Stake by More Than 20,000% May 26 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 

More From Other Websites
Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead May 17 2016
What Lies Ahead for Biotech ETFs? May 13 2016
Will the Current Pipeline Help Medivation Go beyond Xtandi? May 12 2016
The Story behind Medivation’s Rising Collaboration Revenue May 11 2016
A Promising Uptake for Vertex’s Orkambi May 04 2016
Biotech ETFs Sink on Mixed Q1 Results May 02 2016
2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap May 02 2016
Why Is Medivation at a Premium on an EV-to-EBITDA Basis? Apr 14 2016
A Rare Opportunity With A Biotechnology ETF Mar 17 2016
Is The Biotech Bear Market Over? Feb 29 2016
6 Top-Ranked ETFs to Rebound on Bargain Hunt Feb 25 2016
Some Traders Aren't Shy About Betting On A Biotech Rebound Feb 19 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
Tracking The Biotech Bubble's Bust Jan 31 2016
Celgene’s Valuation Is Higher Than Its Peers Jan 25 2016
What Are Analysts’ Expectations for BioMarin? Jan 19 2016
New ETF Is A Refined Pharmaceuticals Play Jan 14 2016
Van Eck Launches Market Vectors® Generic Drugs ETF (GNRX) Jan 13 2016
Bristol-Myers CEO: Looking forward to 2016 Jan 12 2016
BioMarin CEO on drug pricing, approval Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK